Rebound In COVID-19 Symptoms After Pfizer's Antiviral Pill Might Be Due To Stronger Immune Response

Reports are circulating related to recurring COVID-19 symptoms after completing treatment and experiencing improvement after Pfizer Inc's PFE COVID-19 oral antiviral Paxlovid.
President Joe Biden and National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci both experienced a COVID rebound after taking Paxlovid.
The U.S. government researchers have found that the rebound may be related to a robust immune response rather than a weak one, Reuters reports.
Also read: Pfizer's COVID-19 Pill Benefited Only Older Adults, New Israel-Based Study Shows.
The researchers concluded that taking a longer course of the drug - beyond the recommended five days - was not required to reduce the risk of a recurrence, based on an investigation of a rebound in eight patients at the National Institutes of Health's Clinical Center.
The FDA asked Pfizer to test an additional course of Paxlovid among people who experience a rebound in COVID-19 after treatment.
The repot added that all patients in the study had developed robust immune responses but higher levels of antibodies in the patients who experienced a rebound.
None of the rebound patients required additional treatment or hospitalization.
Price Action: PFE shares are down 1.57% at $42.42 on the last check Friday.

Momentum27.90

Growth31.77

Quality65.00

Value31.22

Short

Medium

Long